-The Hindu ‘But cumbersome anti-graft apparatus can delay decisions'   With a slew of scams vitiating the government's policy-making environment and holding up reforms, the Economic Survey 2011-12 on Thursday advocated need for a ruthless crackdown on corruption, but cautioned that a large and cumbersome anti-corruption bureaucracy could impact decision-making. “While we need to ruthlessly crack down on corruption, it must, at the same time, be recognised that the fear of a large and...

-The Economic Times   Could the Centre freeze the job guarantee scheme during peak agriculture season?  The controversial demand from the agriculture ministry found an echo in the Economic Survey released on Thursday, but was quickly dismissed by rural development minister Jairam Ramesh. While lauding the flagship scheme, the survey listed a few other measures as the way forward. "While the overall performance of MGNREGS has been good, there is scope for improvements...

-The Pioneer Hitting at UPA’s biggest flagship scheme Mahatma Gandhi National Rural Employment Guarantee Act (MGNREGA), Agriculture Ministry has criticised the scheme in it’s first ever Agriculture Survey saying that MGNREGA has led to double digit growth in wages annually in the last few years even exceeding the rate of inflation that prevailed during this period. The Agriculture Survey is compiled by the Agriculture Ministry as a precursor to Union Budget on...

The government is likely to peg fertiliser subsidy for next financial year at Rs 66,000 crore, lower than the actual outgo in 2011-12.  "A moderate increase is likely," said a government official. The actual subsidy bill for the fiscal is likely to come at over Rs 70,000 crore though the government had budgeted for just Rs 49,997 crore in the budget 2011-12.  Private analysts had soon after the presentation of the last...

-Reuters India's move to strip German drugmaker Bayer of its exclusive rights to a cancer drug has set a precedent that could extend to other treatments, including modern HIV/AIDS drugs, in a major blow to global pharmaceutical firms, experts say.  On Monday, the Indian Patent Office effectively ended Bayer's monopoly for its Nexavar drug and issued its first-ever compulsory license allowing local generic maker Natco Pharma to make and sell the drug...